(Section title retained for indexing; the source did not report renal endpoints.) The source abstract did not report data on renal outcomes. Investigators focused on maternal overdose, severe maternal morbidity, cardiovascular complications, and neonatal endpoints. Any assessment or inference about renal endpoints would be beyond the information provided in the preprint.
Investigators assembled a retrospective cohort of Tennessee Medicaid–insured pregnant individuals with opioid use disorder between 2010 and 2021. The cohort included 12,327 pregnancies. Prescription exposure was defined as any amphetamine- or methylphenidate-class stimulant that overlapped pregnancy; 380 pregnancies (3.1%) met that exposure definition. The authors reported that stimulant-treated individuals tended to be slightly older and had a higher prevalence of mental health comorbidities compared with unexposed pregnancies. The abstract did not provide additional granular dosing, duration, or timing details for stimulant prescriptions beyond class-level exposure.
The primary maternal outcome was overdose from delivery through one year postpartum. Using overlap weighting to adjust for measured confounders, investigators reported no statistically significant association between prenatal stimulant exposure and postpartum overdose (adjusted odds ratio [aOR], 1.13; 95% CI, 0.61–2.08). Short, direct statement: no clear overdose signal in primary adjusted analyses. Secondary maternal endpoints included death, severe maternal morbidity, and cardiovascular complications within the first six weeks postpartum. Those secondary outcomes were not increased in the overall stimulant-exposed group according to adjusted models. Maternal deaths were described as rare. The preprint did not provide absolute event counts for each maternal outcome in the abstract text.
The investigators selected preterm birth as the primary neonatal outcome. Adjusted analyses showed no association between stimulant exposure and preterm birth (aOR, 1.04; 95% CI, 0.74–1.46). Secondary neonatal outcomes—low birth weight, neonatal opioid withdrawal syndrome (NOWS), and death—were not different between exposed and unexposed groups in adjusted models. One exception emerged: odds of NICU admission were higher among stimulant-exposed infants (aOR, 1.58; 95% CI, 1.17–2.14). Maternal and infant deaths remained rare in the cohort. The authors interpreted the isolated increase in NICU admissions, in the absence of differences in preterm birth, low birth weight, gestational age, or NOWS, as more consistent with intensified surveillance or precautionary monitoring than with a direct neonatal toxic effect. The abstract did not list specific NICU admission diagnoses or lengths of stay.
Investigators conducted exploratory analyses to assess effect modification by medication for OUD and by clinical diagnoses. They evaluated interaction with buprenorphine treatment. The abstract reports that overdose odds were elevated in pregnancies receiving both stimulants and buprenorphine; the interaction reached statistical significance (P for interaction = .03). The authors also reported an elevated cardiovascular composite within the subgroup of pregnancies with ADHD (aOR, 2.33; 95% CI, 1.13–4.82). These findings were explicitly described as exploratory and requiring replication before they can inform clinical practice. The abstract did not provide details on sample sizes within these subgroups or adjusted covariates specific to the subgroup models.
The study is a retrospective analysis of Medicaid claims data in one U.S. state. Claims-based exposure and outcome ascertainment carry known misclassification risks, and the abstract did not provide validation metrics for key variables. The preprint notes that data are not available. Investigators emphasized that the two exploratory signals—the elevated overdose odds with concurrent stimulant and buprenorphine prescriptions, and the increased cardiovascular composite in the ADHD subgroup—require replication in independent cohorts before they can guide clinical decision-making. The authors also stated that these are the first OUD-specific estimates addressing this question, and they concluded that the data do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy. The article is a preprint and has not been peer reviewed; clinicians and policymakers should weigh that status when interpreting the results.
Open questions remaining in the source text include precise dosing and timing of stimulant prescriptions, absolute event counts for several outcomes, and whether increased NICU admissions reflected hospital-level practice patterns versus infant clinical instability. The source did not report those methodological details in the abstract. Replication and peer review are the next explicit steps identified by the study team.